BR112016009749A8 - hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide - Google Patents

hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide

Info

Publication number
BR112016009749A8
BR112016009749A8 BR112016009749A BR112016009749A BR112016009749A8 BR 112016009749 A8 BR112016009749 A8 BR 112016009749A8 BR 112016009749 A BR112016009749 A BR 112016009749A BR 112016009749 A BR112016009749 A BR 112016009749A BR 112016009749 A8 BR112016009749 A8 BR 112016009749A8
Authority
BR
Brazil
Prior art keywords
hydromorphone
naloxone
pain
treatment
dysfunction syndrome
Prior art date
Application number
BR112016009749A
Other languages
English (en)
Inventor
Gerard Hayes Geoffrey
Mohammad Hassan
Kathleen Danagher Helen
Oliver Whitehouse Jonathon
Walden Malcolm
Alberto Vargas Rincon Ricardo
Naganathan Krishnamurthy Thinnayam
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BR112016009749A8 publication Critical patent/BR112016009749A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção refere-se a formas de dosagem farmacêutica de liberação prolongada que compreendem hidromorfona ou um sal farmaceuticamente aceitável do mesmo e naloxona ou um sal farmaceuticamente aceitável do mesmo para uso no tratamento de dor.
BR112016009749A 2013-11-13 2014-11-13 hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide BR112016009749A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13192793 2013-11-13
PCT/EP2014/074537 WO2015071380A1 (en) 2013-11-13 2014-11-13 Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome

Publications (1)

Publication Number Publication Date
BR112016009749A8 true BR112016009749A8 (pt) 2018-01-30

Family

ID=49578189

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009749A BR112016009749A8 (pt) 2013-11-13 2014-11-13 hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide

Country Status (17)

Country Link
US (2) US9814710B2 (pt)
EP (1) EP3068397A1 (pt)
JP (1) JP6232135B2 (pt)
KR (2) KR102194174B1 (pt)
CN (2) CN112716955A (pt)
AU (1) AU2014350135B2 (pt)
BR (1) BR112016009749A8 (pt)
CA (1) CA2929909C (pt)
DE (1) DE112014005175T5 (pt)
EA (1) EA030310B1 (pt)
IL (1) IL245027A0 (pt)
MX (1) MX2016006279A (pt)
NZ (1) NZ719087A (pt)
PH (1) PH12016500666A1 (pt)
SG (1) SG11201602884WA (pt)
UA (1) UA116405C2 (pt)
WO (1) WO2015071380A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340188B (es) 2010-05-10 2016-06-30 Euro-Celtique S A * Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
KR101479388B1 (ko) 2010-05-10 2015-01-05 유로-셀티큐 에스.에이. 활성제 로딩된 과립과 추가의 활성제와의 조합물
SG11201602884WA (en) 2013-11-13 2016-05-30 Euro Celtique Sa Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CA2847781C (en) * 2014-03-28 2019-03-12 Purdue Pharma Reducing drug liking in a subject
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
HU190619B (en) 1983-11-11 1986-09-29 Bezzegh,Denes,Hu Process for producing tablets with controlled dissolution of active ingredients
DE3581428D1 (de) 1984-06-13 1991-02-28 Roehm Gmbh Verfahren zum ueberziehen von arzneiformen.
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5004613A (en) 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
FR2653337B1 (fr) 1989-10-23 1992-02-07 Dow Corning Sa Element a liberation prolongee et procede pour le fabriquer.
JPH03232814A (ja) 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
DE4325465B4 (de) 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE4443105C2 (de) 1994-12-03 1997-03-13 Hoechst Ag Verfahren zur Herstellung Molsidomin-haltiger Tabletten
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
CZ297951B6 (cs) 1997-02-14 2007-05-02 Gödecke Aktiengesellschaft Zpusob stabilizace naloxonu
WO1999001111A1 (en) 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
EP0913152B1 (de) 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
CN1234362C (zh) 1997-12-22 2006-01-04 欧罗赛铁克股份有限公司 阿片样激动剂/阿片样拮抗剂组合物
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6071952A (en) 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
IL149378A0 (en) 1999-11-01 2002-11-10 Rodeva Ltd Composition for treatment of constipation and irritable bowel syndrome
DE10003757A1 (de) 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US20040115133A1 (en) 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
CA2778114A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
ATE493130T1 (de) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
CN100356907C (zh) 2001-06-08 2007-12-26 恩德制药公司 利用丙烯酸酯聚合物的控释剂型和其制备方法
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
WO2003013479A1 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
MXPA04001210A (es) 2001-08-06 2004-07-08 Euro Celtique Sa Formulaciones de agonista opioide con antagonista liberable y aislado.
ES2345327T3 (es) 2001-08-23 2010-09-21 N.V. Organon Proceso para la preparacion de un derivado de 14-hidroxinormorfinona.
DE10144726B4 (de) 2001-09-11 2006-10-05 T-Mobile Deutschland Gmbh Verfahren zur Bereitstellung und Zuteilung von Rufnummern in einem Telekommunikationsnetz
DE10146275A1 (de) 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
EP2289492B1 (en) 2002-03-14 2016-12-07 Euro-Celtique S.A. Naltrexone hydrochloride compositions
DE10215131A1 (de) 2002-04-05 2003-10-16 Euro Celtique Sa Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
LT2425821T (lt) 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
US7407670B2 (en) 2002-07-04 2008-08-05 Janssen Pharmaceutica, N.V. Solid dispersions comprising two different polymer matrixes
US20050004155A1 (en) 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
WO2004091665A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
PT2368553E (pt) 2003-04-08 2015-03-03 Progenics Pharm Inc Formulações farmacêuticas contendo metilnaltrexona
RS20050812A (en) 2003-04-30 2007-12-31 Purdue Pharma L.P., Tamper resistant transdermal dosage form
US9114199B2 (en) 2003-07-31 2015-08-25 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
WO2005034859A2 (en) 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
US20050079221A1 (en) 2003-10-10 2005-04-14 Groenewoud Pieter Jurjen Ibuprofen narcotic composition and method for making same
US20050232987A1 (en) 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
US20050165038A1 (en) 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
ATE406372T1 (de) 2004-02-06 2008-09-15 Euro Celtique Sa Verfahren zur herstellung von 3-o-geschützten morphinonen und 3-o-geschützten morphinondienolcarboxylaten
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
US7700626B2 (en) 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
JP2006076971A (ja) 2004-09-13 2006-03-23 Basf Ag 口腔内崩壊錠
WO2006038226A2 (en) 2004-10-08 2006-04-13 Rubicon Research Pvt. Ltd. Process for making a highly compressible controlled delivery compositions of metformin
GB0423103D0 (en) 2004-10-19 2004-11-17 Boots Healthcare Int Ltd Therapeutic agents
JP2008528497A (ja) 2005-01-20 2008-07-31 プロジェニックス ファーマシューティカルズ，インコーポレーテッド メチルナルトレキソンおよび関連化合物の術後性胃腸障害のための使用
JP5704789B2 (ja) 2005-01-28 2015-04-22 ユーロ−セルティーク エス．エイ． 耐アルコール性剤形
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
JP2008531605A (ja) 2005-03-04 2008-08-14 インテルジェネクス コーポレイション 遅延放出性医薬品経口剤、及びその作製方法
JP4741865B2 (ja) 2005-03-24 2011-08-10 共和薬品工業株式会社 ペルゴリド錠剤の製造方法
US20070026025A1 (en) 2005-04-12 2007-02-01 Aquegel Cosmetics, Llc Topical ointment and method for making and using same
EP1888030A1 (en) 2005-05-25 2008-02-20 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070059360A1 (en) 2005-07-29 2007-03-15 Ashish Jaiswal Water-dispersible anti-retroviral pharmaceutical compositions
US20070048364A1 (en) 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
RU2435592C2 (ru) 2005-12-14 2011-12-10 Ф.Хоффманн-Ля Рош Аг Композиция пролекарства для борьбы с вирусом гепатита с
US20070141147A1 (en) 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102006051020A1 (de) 2006-10-26 2008-04-30 Evonik Röhm Gmbh Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
GB2447898B (en) 2007-03-24 2011-08-17 Reckitt Benckiser Healthcare A tablet having improved stability with at least two actives
MY150600A (en) 2008-07-07 2014-01-30 Euro Celtique Sa Use of opioid antagonists for treating urinary retention
KR101660996B1 (ko) 2008-09-16 2016-09-28 넥타르 테라퓨틱스 남용에 대한 낮은 잠재성을 갖는 페길화 오피오이드
WO2010032073A1 (en) 2008-09-16 2010-03-25 Ak Kimya Ithalat-Ihracat Ve Sanayii Anonim Sirketi Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
AU2009294308B2 (en) 2008-09-18 2013-05-30 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
US9757343B2 (en) 2008-09-24 2017-09-12 Evonik Röhm Gmbh PH-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
PL2326313T3 (pl) 2008-09-24 2015-08-31 Evonik Roehm Gmbh Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu
EP2352494B1 (en) 2008-10-30 2019-10-09 Grünenthal GmbH Novel and potent tapentadol dosage forms
US20100143486A1 (en) 2008-12-10 2010-06-10 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
EP2381937A2 (en) 2008-12-31 2011-11-02 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
EP2385943A4 (en) 2009-01-09 2012-05-30 Harvard College FLUORINATED COMPOUNDS AND METHODS OF USE
AU2010206724A1 (en) 2009-01-22 2011-07-28 Nanotherapeutics, Inc. Process for preparing particles of opioids and compositions produced thereby
AU2010211376B2 (en) 2009-02-06 2013-08-22 Egalet Ltd. Pharmaceutical compositions resistant to abuse
US8431701B2 (en) 2009-02-17 2013-04-30 Mallinckrodt Llc Process for the reductive alkylation of normorphinans
CN102325776A (zh) 2009-02-23 2012-01-18 马林克罗特公司 (+)-吗啡喃*季盐及其制备方法
WO2010096790A1 (en) 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-morphinananium n-oxides and processes for their production
US20100227876A1 (en) 2009-03-06 2010-09-09 Rechfensen Llp Methods of Reducing Side Effects of Analgesics
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
BRPI0924427A2 (pt) 2009-03-18 2016-01-26 Evonik Roehm Gmbh composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma
MX2011009667A (es) 2009-03-18 2011-12-14 Evonik Roehm Gmbh Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante el uso de un revestimiento compuesto de polímeros de vinilo neutrales y excipientes.
CA2756397A1 (en) 2009-04-02 2010-10-07 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
EP2419398A4 (en) 2009-04-14 2012-11-28 Infiniton Ab PRO-BET WITH BETA-KETO-CARBOXYLIC ACID, BETA-KETO-CARBOXYLIC ACID SALT OR BETA-KETO-CARBOXYLIC ACID ESTERS FOR ACTIVE INHIBITION
WO2010123999A2 (en) 2009-04-21 2010-10-28 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
EP2421508B1 (en) 2009-04-24 2016-12-14 Omya International AG Particulate material for controlled release of active ingredients
WO2010141505A1 (en) 2009-06-01 2010-12-09 Protect Pharmaceutical Corporation Abuse-resistant delivery systems
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
CN102803267A (zh) 2009-06-11 2012-11-28 马林克罗特有限公司 通过催化氢转移的6-α-氨基N-取代的吗啡喃的制备
FR2946533A1 (fr) 2009-06-12 2010-12-17 Ethypharm Sa Reduction des fluctuations plasmatiques d'opioides.
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
BR112012001244A2 (pt) 2009-07-22 2020-12-08 Gruünenthal Gmbh Forma de dosagem resitente à adulteração, seu processo de produção, e embalagem contendo tal forma
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
GB0914338D0 (en) 2009-08-17 2009-09-30 Johnson Matthey Plc Improved process
US9493477B2 (en) 2009-09-08 2016-11-15 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
EP2488029B1 (en) 2009-09-30 2016-03-23 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US20110077222A1 (en) 2009-09-30 2011-03-31 Mallinckrodt Inc. Sustained-Release Opiate and Opiate Derivative Compositions
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
CN102724705B (zh) 2009-12-25 2015-04-29 华为技术有限公司 一种报告缓存数据量的方法及装置
MX340188B (es) 2010-05-10 2016-06-30 Euro-Celtique S A * Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
KR101479388B1 (ko) 2010-05-10 2015-01-05 유로-셀티큐 에스.에이. 활성제 로딩된 과립과 추가의 활성제와의 조합물
CH705273B1 (de) 2010-05-10 2016-06-15 Euro Celtique Sa Pharmazeutische Zusammensetzung – umfassend Hydromorphon und Naloxon.
AU2011288413B2 (en) 2010-08-13 2014-05-22 Mundipharma Pty Limited Use of binders for manufacturing storage stable formulations
GB201020895D0 (en) 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
MY162895A (en) * 2010-12-28 2017-07-31 Euro Celtique Sa A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
AR088250A1 (es) 2011-10-06 2014-05-21 Gruenenthal Gmbh Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide
CA2881144A1 (en) 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
SG11201602884WA (en) 2013-11-13 2016-05-30 Euro Celtique Sa Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome

Also Published As

Publication number Publication date
AU2014350135B2 (en) 2017-08-31
AU2014350135A1 (en) 2016-05-12
US9814710B2 (en) 2017-11-14
UA116405C2 (uk) 2018-03-12
CN105916505A (zh) 2016-08-31
DE112014005175T5 (de) 2016-07-21
SG11201602884WA (en) 2016-05-30
EP3068397A1 (en) 2016-09-21
EA030310B1 (ru) 2018-07-31
CN112716955A (zh) 2021-04-30
WO2015071380A1 (en) 2015-05-21
US20180064705A1 (en) 2018-03-08
MX2016006279A (es) 2016-09-07
IL245027A0 (en) 2016-05-31
CA2929909C (en) 2018-08-21
PH12016500666A1 (en) 2016-06-13
EA201690974A1 (ru) 2016-09-30
JP2016539937A (ja) 2016-12-22
JP6232135B2 (ja) 2017-11-15
NZ719087A (en) 2017-12-22
CA2929909A1 (en) 2015-05-21
US10258616B2 (en) 2019-04-16
KR20160060768A (ko) 2016-05-30
US20160296516A1 (en) 2016-10-13
KR20180016651A (ko) 2018-02-14
KR102194174B1 (ko) 2020-12-23

Similar Documents

Publication Publication Date Title
BR112016009749A8 (pt) hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CL2015001891A1 (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas; uso para tratar el dolor; y metodo de preparacion. (divisional de la solicitud n°2754-2014).
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
EA201991484A1 (ru) Лекарственные формы энзалутамида
CO7180189A2 (es) Proceso de síntesis de opioides mejorado
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
BR112013016862A2 (pt) combinação de um agonista de opioide e um antagonista de opioide no tratamento de doença de parkinson
CO7180188A2 (es) Proceso de síntesis de opioides mejorado
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
ES2542042R1 (es) Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
HK1223304A1 (zh) 包含二甲雙胍和二氫槲皮素的藥物組合及其用於治療癌症的用途
IL233693A (en) A system for the translocation of a drug and its use in the treatment of mitochondrial diseases
ES2425315R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
ES2569743R1 (es) Uso de la buprenorfina en la fabricación de un medicamento para tratar los efectos secundarios inducidos por opioides
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
PH12017500923A1 (en) New dosage and use of a a2a antagonist
BR112015023917A2 (pt) método para determinar a atividade de forma potenciada ativada de substância
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
AR100444A1 (es) Uso de palmitoiletanolamida en combinación de opioides
IL238073A0 (en) Pharmacological composition for the treatment of the central nervous system

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements